Stoke Therapeutics (STOK) EBITDA (2018 - 2026)
Stoke Therapeutics (STOK) posted quarterly EBITDA of -$53.4 million for Q1 2026, down 148.02% year-over-year from $111.2 million in Q1 2025, and up 13.06% quarter-over-quarter from -$61.4 million in Q4 2025.
Stoke Therapeutics (STOK) EBITDA (2018 - 2026) Analysis & Trends
Stoke Therapeutics' EBITDA history runs 9 years deep, the most recent figure standing at -$53.4 million for Q1 2026.
- In Q1 2026, EBITDA fell 148.02% year-over-year to -$53.4 million; the TTM figure through Mar 2026 stood at -$185.2 million (down 584.41% YoY), while the FY2025 annual figure was -$20.6 million, up 79.69% from the prior year.
- EBITDA for Q1 2026 stood at -$53.4 million, up from -$61.4 million in the prior quarter.
- The five-year high for EBITDA was $111.2 million in Q1 2025, with the low at -$61.4 million in Q4 2025.
- The 5-year median for EBITDA is -$27.3 million (2025), against an average of -$23.2 million.
- Peak annual rise in EBITDA reached 492.08% in 2025, while the deepest fall reached 350.0% in 2025.
- Stoke Therapeutics' EBITDA stood at -$27.2 million in 2022, then slipped by 8.87% to -$29.6 million in 2023, then soared by 53.85% to -$13.7 million in 2024, then tumbled by 350.0% to -$61.4 million in 2025, then climbed by 13.06% to -$53.4 million in 2026.
- Business Quant data shows STOK's EBITDA at -$53.4 million in Q1 2026, -$61.4 million in Q4 2025, and -$43.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Stoke Therapeutics | 1.95 Bn | 1.66 Bn | - | -65.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -65.43 Mn |
| Mar 31, 2026 | -53.42 Mn |
| Dec 31, 2025 | -61.44 Mn |
| Sep 30, 2025 | -43.09 Mn |
| Jun 30, 2025 | -27.30 Mn |
| Mar 31, 2025 | 111.24 Mn |
| Dec 31, 2024 | -13.65 Mn |
| Sep 30, 2024 | -30.00 Mn |
| Jun 30, 2024 | -29.34 Mn |
| Mar 31, 2024 | -28.37 Mn |
| Dec 31, 2023 | -29.59 Mn |
| Sep 30, 2023 | -27.23 Mn |
| Jun 30, 2023 | -33.26 Mn |
| Mar 31, 2023 | -24.69 Mn |
| Dec 31, 2022 | -27.18 Mn |
| Sep 30, 2022 | -27.15 Mn |
| Jun 30, 2022 | -25.24 Mn |
| Mar 31, 2022 | -24.80 Mn |
| Dec 31, 2021 | -24.53 Mn |
| Sep 30, 2021 | -22.68 Mn |